Major need for safer antiarrhythmic drugs will continue to plague atrial fibrillation market
![](/46/pdcnewsitem/04/24/14/GDnewlogo.jpg)
Despite the restoration and maintenance of sinus rhythm being a common practice in the management of atrial fibrillation, the available antiarrhythmic drugs are of modest efficacy and have unfavorable safety profiles.
Although the overall level of unmet need in the atrial fibrillation market is generally considered moderate, the need for safer antiarrhythmic drugs for the maintenance of sinus rhythm is still a major issue in the treatment space, according to research and consulting firm GlobalData.
The company’s report states that despite the restoration and maintenance of sinus rhythm being a common practice in the management of atrial fibrillation, the available antiarrhythmic drugs are of modest efficacy and have unfavorable safety profiles. For example, amiodarone is a widely used generic antiarrhythmic drug, and despite being considered an effective agent available for heart rhythm control, it has a number of side effects including proarrhythmia, and thyroid, liver, skin, and pulmonary complications.
Jesus Cuaron, GlobaData’s Senior Analyst covering Cardiovascular and Metabolic Disorders, explains: “Antiarrhythmic drug development has been very slow and there are presently no late-stage drug candidates that are expected to address this unmet need by 2025. In addition, most antiarrhythmic drugs are already genericized and more will follow, contributing to a rapid decline in market value from 2022.”
Two of the more promising antiarrhythmic drugs that had just entered, or were expected to enter, Phase III clinical trials, recently had their development discontinued, namely Gilead’s fixed-dose combination of ranolazine/dronedarone and Laguna Pharmaceuticals’ vanoxerine. In the early-stage antiarrhythmic drug pipeline, there are only three drug candidates in Phase II and one drug in Phase I development for atrial fibrillation.
Cuaron explains: “Part of the reason for the low level of activity in the pipeline is due to the high risk involved in developing an antiarrhythmic drug. Large and costly clinical trials are required to demonstrate that a drug is safe and effective, and the track record for those antiarrhythmic drugs that have reached the market in the past decade has been disappointing.
“It is also expected that the availability of cheaper generic alternatives and the continuing cost constraints faced by national health authorities will make it difficult for drugs to obtain reimbursement and subsequent addition to hospital formularies. With continued advances in technology, it is expected that there will be a move towards using procedural technologies, such as catheter ablation, as the preferred treatment option for rhythm control.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance